- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04112667
Functionally Validated Structural Endpoints for Early AMD (ALSTAR2)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) is a prospective cohort study with baseline measurements that are repeated at follow-up 3 years later. The baseline and 3 year follow-up visits will each consist of 2 visits for a total of 4 visits.
Study assessments are listed below. All are collected at two visits at both baseline and follow-up for 4 visits total (blood collection for DNA analysis at baseline only). For some functional tests (photopic and mesonic acuity, photopic and mesonic contrast sensitivity), each eye will be tested separately. For other functional tests (dark-adapted two-color perimetry, light-adapted cone-mediate perimetry, rod-mediated dark adaptation), only one eye will be tested, which will be designated by the study eye. Tropicamide 1% and phenylephrine hydrochloride 2.5% are used to dilate pupils (diameter of ≥ 6 mm) as needed for specific parts of the protocol. After completing the baseline visits, participants will receive an annual phone call from the study coordinator so that contact information can be updated. Participants will receive an annual newsletter containing study related information (this will be submitted to the IRB for approval).
Study Assessments:
- Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light.
- Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors.
- Photopic and mesopic acuity in central vision, as measured by letter charts..
- Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts..
- Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative), OCT-angiography (OCT-A).
- Blood draw for the analysis of C-reactive protein, high-density lipoprotein, carotenoid level, DNA extraction, and examination of the presence of genetic risk associated with age-related macular degeneration (AMD).
- Questionnaires: Demographics, medical co-morbidities, cognitive status screen, medication use, alcohol use, smoking, self-reported visual difficulty in the visual activities of daily living
The Young normal group will only complete:
- Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light.
- Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors.
- . Photopic and mesopic acuity in central vision, as measured by letter charts..
- Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts..
- Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative),OCT-angiography (OCT-A).d and quantitative), OCT-angiography.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
For those in Normal Macular Health or Early AMD: aged ≥ 60 years; either have normal macular health in both eyes at baseline or have early AMD in one eye For Young Normals: aged 20-30 years old; normal macular health in both eyes.
Exclusion Criteria:
Exclusion for those in normal macular health are:
- ANY EYE CONDITION OR DISEASE IN EITHER EITHER (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING:
- diabetic retinopathy
- glaucoma
- ocular hypertension
- history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
- optic neuritis
- corneal disease
- previous ocular trauma or surgery
- REFRACTIVE ERROR >- 6 DIOPTERS
- NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
- multiple sclerosis
- Parkinson disease
- stroke
- Alzheimer disease
- seizure disorders
- brain tumor
- traumatic brain injury
- PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY:
- to follow simple directions
- answer questions about health and functioning
- or to provide informed consent
- DIABETES
- ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRALITY OR IS BELIEVED TO BE TERMINAL.
Exclusion criteria for the early AMD group:
These are identical to those described above, except that it is acceptable for participants to have early AMD (AREDS 2-4) in one eye and be AREDS grade 1 or any stage of AMD in the fellow eye.
Exclusion for Young Normals:
- ANY EYE CONDITION OR DISEASE IN EITHER EYE (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING:
- diabetic retinopathy
- glaucoma
- ocular hypertension
- history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations)
- optic neuritis, corneal disease
- previous ocular trauma or surgery
- RERACTIVE ERROR >=6 DIOPTORS
- NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING:
- multiple sclerosis
- Parkinson disease
- stroke
- Alzheimer disease
- seizure disorders
- brain tumor
- traumatic brain injury
- PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY TO:
- follow simple directions
- answer questions about health and functioning
- or to provide informed consent
- DIABETES
- ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRAILTY OR IS BELIEVED TO BE TERMINAL.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Normal Macular Health
>=60 years old with no macular disease
|
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity).
Age-related macular degeneration status will be determined by multi-modal imaging.
|
Early Macular Degeneration
>=60 years old with early age-related macular degeneration
|
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity).
Age-related macular degeneration status will be determined by multi-modal imaging.
|
Young Normals
20-30 years old with normal macular health
|
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity).
Age-related macular degeneration status will be determined by multi-modal imaging.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rod-mediated dark adaptation
Time Frame: Measured at baseline enrollment
|
Time required to recover light sensitivity after exposure to bright light
|
Measured at baseline enrollment
|
Rod-mediated dark adaptation
Time Frame: Measured at 3 years after baseline enrollment
|
Time required to recover light sensitivity after exposure to bright light
|
Measured at 3 years after baseline enrollment
|
incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging
Time Frame: Measured at baseline enrollment
|
development of AMD or progression of AMD at the 3 year follow up visit
|
Measured at baseline enrollment
|
incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging
Time Frame: Measured at 3 years after baseline enrollment
|
development of AMD or progression of AMD at the 3 year follow up visit
|
Measured at 3 years after baseline enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Light sensitivity as measured by microperimetry and perimetry
Time Frame: Measured at baseline enrollment
|
Amount of light needed to detect a small target object
|
Measured at baseline enrollment
|
Light sensitivity as measured by microperimetry and perimetry
Time Frame: Measured at 3 years after baseline enrollment
|
Amount of light needed to detect a small target object
|
Measured at 3 years after baseline enrollment
|
Photopic and mesopic acuity
Time Frame: Measured at baseline enrollment
|
Visual acuity under day time and twilight conditions
|
Measured at baseline enrollment
|
Photopic and mesopic acuity
Time Frame: Measured at 3 years after baseline enrollment
|
Visual acuity under day time and twilight conditions
|
Measured at 3 years after baseline enrollment
|
Photopic and mesopic contrast sensitivity
Time Frame: Measured at baseline enrollment
|
Amount of contrast needed to recognize a letter under day time and twilight conditions
|
Measured at baseline enrollment
|
Photopic and mesopic contrast sensitivity
Time Frame: Measured at 3 years after baseline enrollment
|
Amount of contrast needed to recognize a letter under day time and twilight conditions
|
Measured at 3 years after baseline enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Cynthia Owsley, PhD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R01EY029595 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
Clinical Trials on Normal Macular Health
-
King's College Hospital NHS TrustNational Institute for Health Research, United KingdomNot yet recruitingMacular Holes
-
Moorfields Eye Hospital Centre Abu DhabiUniversity of Nebraska; King Khaled Eye Specialist HospitalCompletedDiabetic Macular EdemaUnited Arab Emirates
-
Sun Yat-sen UniversityCompleted
-
Central Hospital, Nancy, FranceUnknown
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Kyorin UniversityCompletedMacular Hole Surgery
-
Sun Yat-sen UniversitySuspended
-
Anna Rita Daniele, MDAlcon ResearchCompletedComparison of 3D Visualization and Microscope for VR SurgeryItaly
-
Minia UniversityUnknownRetinal Detachment | Myopic Macular Degeneration | Macula HoleEgypt